Our blog is a forum for discussion of new ideas in the field of antibody technology, discovery, and development.
06/08/2016Antibody Solutions at BIO 2016
Antibody Solutions has spent the last two days at the BIO 2016 conference. And what a whirlwind it has been so far! BIO is one of, if not the largest conference of the industry and spans all three buildings of the Moscone Center in San Francisco. The thousands of visitors, keynotes, talks, reception... ...more, comments
01/15/2015Antibody Solutions at RESI Conference
Antibody Solutions attended the RESI Conference in January 2015. The RESI conference is a satellite meeting of the JP Morgan Healthcare conference held every January in San Francisco. It brings together an interesting mix of entrepreneurs and investors. ...more, comments
04/15/2014Bristol-Myers Squibb Acquires iPierian, Inc.
Bristol-Myers Squibb announced today that it had acquired iPierian, Inc. The acquisition gives Bristol-Myers Squibb full rights to iPierian's lead asset IPN007, an innovative preclinical monoclonal antibody that represents a promising new approach to treat progressive supranuclear palsy (PSP) and o... ...more, comments
11/30/2013Cadherin-11 EC1 Domain Antagonists
United States Patent no. 8,591,888, issued on Nov. 26, to Synovex Corp. (Medford, Mass.). The patent "Cadherin-11 EC1 Domain Antagonists for Treating Inflammatory Joint Disorders" by James G. McArthur of Synovex describes antibodies created using Antibody Solutions discovery antibody services. ...more, comments